Quick Answer
Shuttle Pharmaceuticals Holdings, Inc. reported Operating Income Loss of -$11.92 million for the year ending 2025.
- Shuttle Pharmaceuticals Holdings, Inc. showed a decrease of -54.8% in Operating Income Loss from 2024 to 2025.
- This data is from Shuttle Pharmaceuticals Holdings, Inc.'s annual report (Form 10-K), filed with the SEC on March 31, 2026.
- XBRL data for this metric is available from 2021 to 2025 (5 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Quarterly values from 10-Q filings: Q3 2021: -$242.1 thousand | Q1 2022: -$638.4 thousand | Q2 2022: -$353.6 thousand | Q3 2022: -$821.5 thousand | Q1 2023: -$1.54 million | Q2 2023: -$1.47 million | Q3 2023: -$1.60 million | Q1 2024: -$1.38 million | Q2 2024: -$1.48 million | Q3 2024: -$3.05 million | Q1 2025: -$2.95 million | Q2 2025: -$3.91 million | Q3 2025: -$2.27 million.
- Over the full 5 years of available data (2021 to 2025), Shuttle Pharmaceuticals Holdings, Inc.'s Operating Income Loss has declined by 583.7%.
- Historical annual values: Fiscal year 2025: -$11.92 million | Fiscal year 2024: -$7.70 million | Fiscal year 2023: -$5.89 million | Fiscal year 2022: -$2.55 million | Fiscal year 2021: -$1.74 million.
- Data sourced from SEC EDGAR public filings as of August 10, 2026.
Last verified: